Literature DB >> 19384898

Over-expression of SUMO-1 induces the up-regulation of heterogeneous nuclear ribonucleoprotein A2/B1 isoform B1 (hnRNP A2/B1 isoform B1) and uracil DNA glycosylase (UDG) in hepG2 cells.

Kit Wan Ma1, Shannon W N Au, Mary M Y Waye.   

Abstract

Sumoylation is one of the post-translational modifications that governs many cellular activities, including subcellular localization targeting, protein-protein interaction, and transcriptional activity regulation. SUMO E3 ligases are responsible for substrate specificity determination in which PIAS is the largest E3 family that consists of five members in human; they are PIAS1, PIAS3, PIASx alpha, PIASx beta, and PIASy. Several studies showed that all these PIAS genes are highly expressed in testis but only a few reports have discussed their expression pattern in other tissues. Though liver is a multifunctional organ and one would expect to find regulation of cellular functions by sumoylation, the identified sumoylation substrates are scarce and few of them correlate with liver cancer. In this report, we have found that PIASx alpha, PIASx beta, and PIASy are highly expressed in liver as well as testis by tissue distribution studies. We thus aimed to identify any SUMO-1 related proteins in liver cancer cells by two-dimensional gel electrophoresis and mass spectrometry. Two up-regulated proteins, heterogeneous nuclear ribonucleoprotein A2/B1 isoform B1 (hnRNP A2/B1 isoform B1) and uracil DNA glycosylase (UDG), have been identified in the EGFP-SUMO-1 over-expressing HepG2 cells. The up-regulation is suggested to be mediated via changes at the translational level or protection from degradation by western blotting and RT-PCR. 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19384898     DOI: 10.1002/cbf.1562

Source DB:  PubMed          Journal:  Cell Biochem Funct        ISSN: 0263-6484            Impact factor:   3.685


  8 in total

1.  Anti-inflammatory effect of insulin in the human hepatoma cell line HepG2 involves decreased transcription of IL-6 target genes and nuclear exclusion of FOXO1.

Authors:  Emelie Wallerstedt; Madeléne Sandqvist; Ulf Smith; Christian X Andersson
Journal:  Mol Cell Biochem       Date:  2011-02-05       Impact factor: 3.396

2.  Up-regulation and subcellular localization of hnRNP A2/B1 in the development of hepatocellular carcinoma.

Authors:  Huaqing Cui; Feng Wu; Yanling Sun; Guocai Fan; Qingming Wang
Journal:  BMC Cancer       Date:  2010-07-06       Impact factor: 4.430

3.  hnRNPA2/B1 activates cyclooxygenase-2 and promotes tumor growth in human lung cancers.

Authors:  Yang Xuan; Jingshu Wang; Liying Ban; Jian-Jun Lu; Canhui Yi; Zhenglin Li; Wendan Yu; Mei Li; Tingting Xu; Wenjing Yang; Zhipeng Tang; Ranran Tang; Xiangsheng Xiao; Songshu Meng; Yiming Chen; Quentin Liu; Wenlin Huang; Wei Guo; Xiaonan Cui; Wuguo Deng
Journal:  Mol Oncol       Date:  2015-11-30       Impact factor: 6.603

Review 4.  Base Excision Repair, a Pathway Regulated by Posttranslational Modifications.

Authors:  Rachel J Carter; Jason L Parsons
Journal:  Mol Cell Biol       Date:  2016-05-02       Impact factor: 4.272

5.  Transient protection from heat-stress induced apoptotic stimulation by metastasis-associated protein 1 in pachytene spermatocytes.

Authors:  Wei Li; Zhi-qun Wu; Jie Zhao; Sheng-jie Guo; Zhen Li; Xiao Feng; Li Ma; Jin-shan Zhang; Xin-ping Liu; Yuan-qiang Zhang
Journal:  PLoS One       Date:  2011-10-12       Impact factor: 3.240

6.  Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression.

Authors:  Fat-Moon Suk; Shyr-Yi Lin; Ren-Jye Lin; Yung-Hsin Hsine; Yen-Ju Liao; Sheng-Uei Fang; Yu-Chih Liang
Journal:  Oncotarget       Date:  2015-09-22

7.  SUMO1 promotes the proliferation and invasion of non-small cell lung cancer cells by regulating NF-κB.

Authors:  Changkang Ke; Kai Zhu; Ying Sun; Yunfeng Ni; Zhipei Zhang; Xiaofei Li
Journal:  Thorac Cancer       Date:  2018-11-04       Impact factor: 3.500

Review 8.  Focus on DNA Glycosylases-A Set of Tightly Regulated Enzymes with a High Potential as Anticancer Drug Targets.

Authors:  Fabienne Hans; Muge Senarisoy; Chandini Bhaskar Naidu; Joanna Timmins
Journal:  Int J Mol Sci       Date:  2020-12-03       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.